Loading...
XSHE002566
Market cap318mUSD
Dec 27, Last price  
7.02CNY
1D
1.74%
1Q
4.78%
Jan 2017
-45.16%
IPO
-46.53%
Name

Jilin Jian Yisheng Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002566 chart
P/E
24.52
P/S
2.72
EPS
0.29
Div Yield, %
1.29%
Shrs. gr., 5y
—
Rev. gr., 5y
-2.62%
Revenues
854m
+2.85%
226,373,903267,837,384311,753,125414,884,408516,224,102528,925,262600,503,234643,896,712787,894,295819,598,117939,012,6281,034,442,376975,088,2001,012,748,483842,589,907877,929,541830,041,323853,664,904
Net income
95m
+14.00%
23,471,69336,109,52341,366,69761,128,77087,637,99096,484,10596,626,83087,319,04996,408,83010,911,48513,194,41160,069,57469,079,28276,598,73680,060,08596,020,34983,096,99494,732,729
CFO
209m
+43.38%
0020,497,435125,246,25550,725,273079,078,5930000270,654,341167,318,427210,871,994203,514,966215,100,714145,856,177209,130,115
Dividend
May 22, 20240.15 CNY/sh
Earnings
May 09, 2025

Profile

Jilin Jian Yisheng Pharmaceutical Co., Ltd. manufactures and sells medicine, Chinese herbal medicine, cosmetics, and food products in China. It offers capsules, injections, tablets, granules, and other products; and Ginseng medicinal and bee products. Jilin Jian Yisheng Pharmaceutical Co., Ltd. was founded in 1997 and is based in Ji'an, China.
URL
http://www.yisheng-pharm.com/
IPO date
Mar 18, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
853,665
2.85%
830,041
-5.45%
877,930
4.19%
Cost of revenue
568,384
658,090
688,514
Unusual Expense (Income)
NOPBT
285,281
171,951
189,416
NOPBT Margin
33.42%
20.72%
21.58%
Operating Taxes
15,652
12,907
18,672
Tax Rate
5.49%
7.51%
9.86%
NOPAT
269,630
159,044
170,744
Net income
94,733
14.00%
83,097
-13.46%
96,020
19.94%
Dividends
(29,857)
(9,929)
(9,929)
Dividend yield
1.01%
0.37%
0.33%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
470,433
433,721
403,718
Long-term debt
8,053
19,649
22,927
Deferred revenue
118,023
120,846
Other long-term liabilities
118,694
1
1
Net debt
(112,230)
50,264
133,798
Cash flow
Cash from operating activities
209,130
145,856
215,101
CAPEX
(35,772)
Cash from investing activities
1,768
Cash from financing activities
8,734
FCF
322,245
191,262
67,890
Balance
Cash
590,716
403,107
289,858
Long term investments
1
2
2,989
Excess cash
548,033
361,605
248,951
Stockholders' equity
1,357,516
1,455,619
1,404,476
Invested Capital
2,377,541
2,430,572
2,454,971
ROIC
11.22%
6.51%
7.08%
ROCE
9.75%
6.16%
7.01%
EV
Common stock shares outstanding
330,952
330,952
330,952
Price
8.90
9.88%
8.10
-10.40%
9.04
35.74%
Market cap
2,945,469
9.88%
2,680,708
-10.40%
2,991,802
35.74%
EV
2,932,496
2,825,422
3,242,075
EBITDA
334,208
216,222
232,504
EV/EBITDA
8.77
13.07
13.94
Interest
13,777
14,033
13,360
Interest/NOPBT
4.83%
8.16%
7.05%